Targeting the niche is a new strategy to eliminate persistent and drug-resistant LSCs.
2
This represents a novel approach to more effectively target LSCs in patients receiving TKI treatment.
3
No relapse occurred in the eight patients still on TKI therapy, whether LSCs were detectable or not.
4
These cells are thought to be responsible for relapse and are termed leukemia stem cells (LSCs).
5
These findings indicate that clinically relevant eradication of LSCs can be achieved with drugs that target LSC metabolic vulnerabilities.
6
Finally, it emphasizes the difficulty of detecting residual LSCs due to their rarity and their low BCR-ABL1 mRNA expression.
7
We found abnormal profiles only for H3K79me2 on MLL-AF9 fusion target loci in LSCs.
8
Our findings point to a promising epigenetic-based therapeutic strategy to more effectively target LSCs in patients with CML receiving TKIs.
9
This simple and inexpensive approach will facilitate basic investigation of LSCs and enable screening of novel therapeutic agents targeting LSCs.
10
In a mouse model in which both pathways are activated in stem and progenitor cells, LSCs expanded under chemotherapy-induced stress.
11
MAGI2-AS3 exhibited a poor expression level in LSCs than the normal human haematopoietic stem cells.
12
This is primarily caused by resisting leukemic stem cells (LSCs), which prevent achievement of treatment-free remission in all patients.
13
Here we studied the ability of MSCs to support the growth and survival of leukemic stem cells (LSCs) in vitro.
14
Aim: To explore the effects and mechanism of the spleen on the proliferation and differentiation of LSCs in PH due to liver cirrhosis.
15
Leukaemia stem cells (LSCs) initiate and maintain the clonal hierarchy of AML and exhibit properties of self-renewal remaining recalcitrant to conventional chemotherapy.
16
Radioactivity recovery in HPLC-MSC analysis was reliably determined using an LSC-based method.